J 1999

Interaction of five gene polymorphism at psoriasis

VAŠKŮ, Vladimír, Anna VAŠKŮ, Lydie IZAKOVIČOVÁ HOLLÁ, Kateřina KAŇKOVÁ, Vladimír ZNOJIL et. al.

Basic information

Original name

Interaction of five gene polymorphism at psoriasis

Authors

VAŠKŮ, Vladimír (203 Czech Republic, guarantor), Anna VAŠKŮ (203 Czech Republic), Lydie IZAKOVIČOVÁ HOLLÁ (203 Czech Republic), Kateřina KAŇKOVÁ (203 Czech Republic), Vladimír ZNOJIL (203 Czech Republic), Věra SEMRÁDOVÁ (203 Czech Republic) and Jiří VÁCHA (203 Czech Republic)

Edition

The Journal of Investigative Dermatology, Cambridge, Blackwell Science Inc. 1999, 0022-202X

Other information

Language

English

Type of outcome

Článek v odborném periodiku

Field of Study

30216 Dermatology and venereal diseases

Country of publisher

United States of America

Confidentiality degree

není předmětem státního či obchodního tajemství

Impact factor

Impact factor: 4.903

RIV identification code

RIV/00216224:14110/99:00002134

Organization unit

Faculty of Medicine

UT WoS

000082406000405

Keywords in English

gene; polymorphism; TAP; TNF; endothelin; ACE
Změněno: 17/6/2009 13:14, prof. MUDr. Lydie Izakovičová Hollá, Ph.D.

Abstract

V originále

Associations among five gene polymorphism interactions and clinically manifested psoriasis were studied. All studied gene polymorphisms (endothelin-1-ET-1, transporters associated with antigen processing-TAP1, tumor necrosis factor beta-TNF beta, angiotensin I converting enzyme-ACE, advanced glycosylation end product-specific receptor- RAGE) were analyzed for their possible participation in the MHC class I cell surface antigen presentation to CD8+ T-cells. In psoriatic patients (n=153), the disequilibrium was found for coincidence of TNF beta with TAPl-333 ( P=0.016) as well as with TAP1-637 ( P=0.035). TNF beta was in disequilibrium with (ACE) polymorphism (P=0.036). ACE was observed to be in tight disequilibrium with TAP1-333 (p= 0.009) but not with TAP1-637 (P=0.133). The borderline significance of disequilibrium was found for ET-1 and RAGE gene polymorphisms (P=0.07).

Links

GA306/93/2192, research and development project
Name: Polymorfismy genů pro angiotensinogen a angiotensin I konvertasu u esenciální hypertense.
Investor: Czech Science Foundation, Polymorphisms of Genes Coding for Angiotensinogen and Angiotensin I Convertase in Essential Hypertension
GA306/96/0099, research and development project
Name: Polymorfismus genu pro endotelin - 1 (EDN 1) u esenciální hypertense
Investor: Czech Science Foundation, Polymorphism of endothelin - 1 gene (EDN 1) in essential hypertension
MSM 141100002, plan (intention)
Name: Molekulární patofyziologie multigenních chorob
Investor: Ministry of Education, Youth and Sports of the CR, Molecular pathophysiology of multigene diseases
VS96097, research and development project
Name: Molekulární patofyziologie vybraných "civilizačních", multigenně podmíněných chorob
Investor: Ministry of Education, Youth and Sports of the CR, Molecular pathophysiology of selected multigenic related to civilization diseases